| ISSN |
2220-3230 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Retrospective Study |
| Article Title |
Transarterial embolization is an acceptable bridging therapy to hepatocellular carcinoma prior to liver transplantation
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Gabriel Lazzarotto-da-Silva, Leandro A Scaffaro, Mauricio Farenzena, Lucas Prediger, Rafaela K Silva, Flávia Heinz Feier, Tomaz J M Grezzana-Filho, Pablo D Rodrigues, Alexandre de Araujo, Mario Reis Alvares-da-Silva, Roberta C Marchiori, Cleber Rosito Pinto Kruel and Marcio Fernandes Chedid |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| Financiamento e Incentivo à Pesquisa (FIPE/HCPA) of Hospital de Clínicas de Porto Alegre |
No. 2020-0473 |
|
| Corresponding Author |
Marcio Fernandes Chedid, MD, MSc, PhD, Professor, Department of Liver Transplant and Hepatobiliary Surgery Unit, Hospital de Clínicas de Porto Alegre, Rua Ramiro Barcelos 2350
, Porto Alegre 90035-007, RS, Brazil. mchedid@hcpa.edu.br |
| Key Words |
Hepatocellular carcinoma; Transarterial embolization; Transarterial chemoembolization; Liver transplantation; Locoregional therapy; Bridging |
| Core Tip |
Hepatocellular carcinoma (HCC) is an aggressive malignant neoplasm, and the treatment of choice is liver transplantation (LT). Because the waiting time is often unpredictable, locoregional therapy is used to halt HCC progression until an organ is available. Although largely replaced by transarterial chemoembolization (TACE), transarterial embolization (TAE) or bland embolization is an alternative with a lower cost and safer adverse event profile. Our findings, in conjunction with those of previous studies, provide evidence of non-superiority of TACE over TAE, thereby encouraging a more liberal use of TAE for bridging HCC to LT. |
| Publish Date |
2024-06-14 08:01 |
| Citation |
Lazzarotto-da-Silva G, Scaffaro LA, Farenzena M, Prediger L, Silva RK, Feier FH, Grezzana-Filho TJM, Rodrigues PD, de Araujo A, Alvares-da-Silva MR, Marchiori RC, Kruel CRP, Chedid MF. Transarterial embolization is an acceptable bridging therapy to hepatocellular carcinoma prior to liver transplantation. World J Transplant 2024; 14(2): 90571 |
| URL |
https://www.wjgnet.com/2220-3230/full/v14/i2/90571.htm |
| DOI |
https://dx.doi.org/10.5500/wjt.v14.i2.90571 |
